Clinical Evaluation of a Novel Insulin Immunosensor

BACKGROUND

The estimation of available active insulin remains a limitation of automated insulin delivery systems. Currently, insulin pumps calculate active insulin using mathematical decay curves, while quantitative measurements of insulin would explicitly provide person-specific PK insulin dynamics to assess remaining active insulin more accurately, permitting more effective glucose control.

METHODS

We performed the first clinical evaluation of an insulin immunosensor chip, providing near real-time measurements of insulin levels. In this study, we sought to determine the accuracy of the novel insulin sensor and assess its therapeutic risk and benefit by presenting a new tool developed to indicate the potential therapeutic consequences arising from inaccurate insulin measurements.

RESULTS

Nine adult participants with type-1 diabetes completed the study. The change from baseline in immunosensor-measured insulin levels was compared with values obtained by standard enzyme-linked immunosorbant assay (ELISA) after preprandial injection of insulin. The point-of-care quantification of insulin levels revealed similar temporal trends as those from the laboratory insulin ELISA. The results showed that 70% of the paired immunosensor-reference values were concordant, which suggests that the patient could take action safely based on insulin concentration obtained by the novel sensor.

CONCLUSIONS

This proposed technology and preliminary feasibility evaluation show encouraging results for near real-time evaluation of insulin levels, with the potential to improve diabetes management. Real-time measurements of insulin provide person-specific insulin dynamics that could be used to make more informed decisions regarding insulin dosing, thus helping to prevent hypoglycemia and improve diabetes outcomes.

Development of a Novel Insulin Sensor for Clinical Decision-Making

BACKGROUND

Clinical decision support systems that incorporate information from frequent insulin measurements to enhance individualized diabetes management remain an unmet goal. The development of a disposable insulin strip for fast decentralized point-of-care detection replacing the current centralized lab-based methods used in clinical practice would be highly desirable to improve the establishment of individual insulin absorption patterns and algorithm modeling processes.

METHODS

We carried out the development and optimization of a novel decentralized disposable insulin electrochemical sensor focusing on obtaining high analytical and operational performance toward achieving a true point-of-care insulin testing device for clinical on-site application.

RESULTS

Our novel insulin immunosensor demonstrated an attractive performance and efficient user-friendly operation by providing high sensitivity capability to detect endogenous and analog insulin with a limit of detection of 30.2 pM (4.3 µiU/mL), rapid time-to-result, stability toward remote site application, and scalable low-cost fabrication with an estimated cost-of-goods for disposable consumables of below $5, capable of near real-time insulin detection in a microliter (≤10 µL) sample droplet of undiluted serum within 30 minutes.

CONCLUSIONS

The results obtained in the optimization and characterization of our novel insulin sensor illustrate its suitability for its potential application in remote clinical environments for frequent insulin monitoring. Future work will test the insulin sensor in a clinical research setting to assess its efficacy in individuals with type 1 diabetes.

Nanomaterial-based aptasensors as an efficient substitute for cardiovascular disease diagnosis: Future of smart biosensors

As a major cause of deaths in developed countries, cardiovascular disease (CVD) has been a big burden for human health systems. Its early and rapid detection is crucial to efficiently apply appropriate on time therapy and to ultimately reduce the associated mortality rate. Aptamers, known as single-stranded DNA/RNA or oligonucleotides containing receptors and/or catalytic properties, have been widely employed in biodetection platforms due to their beneficial properties. Like antibodies, aptamers have served as artificial target receptors in affinity biosensors. Currently, advanced biosensors with improved sensitivity and specificity are fabricated by the synergistic combination of aptamers and diverse nanomaterials. Herein, we review the current development and applications of nanomaterial-based aptasensors for the recognition of CVD biomarkers with special emphasis on electrochemical and optical technologies. The performance of aptasensors has been assessed further in terms of key quality assurance metrics along with discussions on recent technologies developed for the amplification of signals with enhanced portability.

An ultrasensitive electrochemical aptasensor based on a single-stranded aptamer-Au@Fe-MIL-88 complex using methylene blue as an electrochemical probe for insulin detection

This work introduces an electrochemical aptasensor based on a single-stranded aptamer-Au@Fe-MIL-88 complex for sensitive and selective determination of insulin using differential pulls voltammetry. Au@Fe-MIL-88 with a large surface area was synthesized and employed as a suitable substrate for immobilization of the aptamer (APT-Au@Fe-MIL-88). Methylene blue (MB), as an electrochemical probe, was intercalated into the aptamer. Graphene oxide (GO) and zinc sulfide (ZnS) were placed on the Au electrode to amplify the MB current. Also, ZnS improves the immobilization of APT-Au@Fe-MIL-88 into the aptasensor through the strong interaction of Au-S. In the presence of the insulin, MB is released from the aptamer due to DNA conformational change, and as a result, the peak intensity of the intercalated MB was decreased. Under optimal conditions, the change in the current of MB was proportional to the insulin concentration in the range of 5.0 × 10^-16-5.0 × 10^-11 mol L^-1, with a superior ultra-low detection limit of 1.3 × 10^-16 mol L^-1. It was observed that the aptasensor is suitable for determining insulin in serum samples with good sensitivity and reproducibility and with recoveries ranging from 96.4 to 102.0%. The relative standard deviations (RSD) were lower than 3.8% (n = 3).

Electrochemical Mini-Platform with Thread based Electrodes for Interference Free Arsenic Detection

Herein, a fully integrated thread/textile-based electrochemical sensing device has been demonstrated. A hydrophilic conductive carbon thread, chemically modified with gold nanoparticles through an electrodeposition process, was used as a working electrode (WE). The hydrophilic thread coated with Ag/AgCl and an unmodified bare hydrophilic thread were used as reference electrode (RE) and counter electrode (CE) respectively. The device was fabricated with hydrophilic conductive carbon threads supported by capillary tubes and these integrated electrodes were placed in a 2 mL glass vial. The physico-chemical characterization of the working electrode was carried out using SEM (scanning electron microscopy) and X-ray photoelectron spectroscopy (XPS). Furthermore, the fabricated sensing platform, was tested for electrochemical sensing of arsenic. The electrocatalytic oxidation activity of arsenic in the designed platform was investigated via cyclic voltammetry (CV) and square wave Voltammetry (SWV). An oxidation peak at -0.4 V corresponding to the oxidation of arsenic was obtained. Scan rate effect was performed using CV analysis and the diffusion coefficient was found to be 2.478×10-10 with a regression coefficient of R2 = 0.9647. Further, concentration effect was accomplished in the linear range 0.4 μM to 60 μM. The limit of detection was obtained as 0.416 μM. For the practical application, effect of interference from other chemicals and real sample analysis from the tap water and blood serum sample was carried out which gave remarkable recovery values.

Evaluation of single and combined toxicity of bisphenol A and its analogues using a highly-sensitive micro-biosensor

Bisphenol analogues have been developed as alternatives to bisphenol A (BPA), a common chemical with potential adverse effects on human health. It is imperative to perform a fast and sensitive evaluation for the toxicity of these bisphenol analogues. This study introduces a label-free electrochemical biosensor based on a screen-printed electrode modified with the carboxylated multi-walled carbon nanotube/rhodamine B/gold nanoparticle. Ctenopharyngodon idella kidney (CIK) cells were used as the biological recognition agent to detect changes in electrochemical signals and indicate the cell viability. Only 20 μL of sample was required for detection, which was much lower than that of other conventional electrochemical methods (≥ 1 mL). This biosensor was examined for the cytotoxicity of BPA, bisphenol AF (BPAF), bisphenol B (BPB), bisphenol F (BPF), and bisphenol S (BPS) to CIK cells. The half inhibition concentration (IC₅₀) values after 48 h of exposure indicated that the rank order of cytotoxicities was BPAF > BPB > BPA > BPF > BPS. The morphological changes in CIK cells after treatment with various bisphenols were investigated, and the combined toxicities of the binary bisphenol mixtures were determined. Potentially synergistic and additive effects were observed. These findings provide new insights into the cytotoxicity of bisphenol analogues.

Recent advances in designing nanomaterial based biointerfaces for electrochemical biosensing cardiovascular biomarkers

Early diagnosis of cardiovascular disease (CVD) is critically important for successful treatment and recovery of patients. At present, detection of CVD at early stages of its progression becomes a major issue for world health. The nanoscale electrochemical biosensors exhibit diverse outstanding properties, rendering them extremely suitable for the determination of CVD biomarkers at very low concentrations in biological fluids. The unique advantages offered by electrochemical biosensors in terms of sensitivity and stability imparted by nanostructuring the electrode surface together with high affinity and selectivity of bioreceptors have led to the development of new electrochemical biosensing strategies that have introduced as interesting alternatives to conventional methodologies for clinical diagnostics of CVD. This review provides an updated overview of selected examples during the period 2005-2018 involving electrochemical biosensing approaches and signal amplification strategies based on nanomaterials, which have been applied for determination of CVD biomarkers. The studied CVD biomarkers include AXL receptor tyrosine kinase, apolipoproteins, cholesterol, C-reactive protein (CRP), D-dimer, fibrinogen (Fib), glucose, insulin, interleukins, lipoproteins, myoglobin, N-terminal pro-B-type natriuretic peptide (BNP), tumor necrosis factor alpha (TNF-α) and troponins (Tns) on electrochemical transduction format. Identification of new specific CVD biomarkers, multiplex bioassay for the simultaneous determination of biomarkers, emergence of microfluidic biosensors, real-time analysis of biomarkers and point of care validation with high sensitivity and selectivity are the major challenges for future research.

Electrochemical and surface plasmon insulin assays on clinical samples

Diabetes is a complex immune disorder that requires extensive medical care beyond glycemic control. Recently, the prevalence of diabetes, particularly type 1 diabetes (T1D), has significantly increased from 5% to 10%, and this has affected the health-associated complication incidences in children and adults. The 2012 statistics by the American Diabetes Association reported that 29.1 million Americans (9.3% of the population) had diabetes, and 86 million Americans (age ≥20 years, an increase from 79 million in 2010) had prediabetes. Personalized glucometers allow diabetes management by easy monitoring of the high millimolar blood glucose levels. In contrast, non-glucose diabetes biomarkers, which have gained considerable attention for early prediction and provide insights about diabetes metabolic pathways, are difficult to measure because of their ultra-low levels in blood. Similarly, insulin pumps, sensors, and insulin monitoring systems are of considerable biomedical significance due to their ever-increasing need for managing diabetic, prediabetic, and pancreatic disorders. Our laboratory focuses on developing electrochemical immunosensors and surface plasmon microarrays for minimally invasive insulin measurements in clinical sample matrices. By utilizing antibodies or aptamers as the insulin-selective biorecognition elements in combination with nanomaterials, we demonstrated a series of selective and clinically sensitive electrochemical and surface plasmon immunoassays. This review provides an overview of different electrochemical and surface plasmon immunoassays for insulin. Considering the paramount importance of diabetes diagnosis, treatment, and management and insulin pumps and monitoring devices with focus on both T1D (insulin-deficient condition) and type 2 diabetes (insulin-resistant condition), this review on insulin bioassays is timely and significant.

Noble metal nanostructures in optical biosensors: Basics, and their introduction to anti-doping detection

Nanotechnology has illustrated significant potentials in biomolecular-sensing applications; particularly its introduction to anti-doping detection is of great importance. Illicit recreational drugs, substances that can be potentially abused, and drugs with dosage limitations according to the prohibited lists announced by the World Antidoping Agency (WADA) are becoming of increasing interest to forensic chemists. In this review, the theoretical principles of optical biosensors based on noble metal nanoparticles, and the transduction mechanism of commonly-applied plasmonic biosensors are covered. We review different classes of recently-developed plasmonic biosensors for analytic determination and quantification of illicit drugs in anti-doping applications. The important classes of illicit drugs include anabolic steroids, opioids, stimulants, and peptide hormones. The main emphasis is on the advantages that noble metal nano-particles bring to optical biosensors for signal enhancement and the development of highly sensitive (label-free) biosensors. In the near future, such optical biosensors may be an invaluable substitute for conventional anti-doping detection methods such as chromatography-based approaches, and may even be commercialized for routine anti-doping tests.

A sensitive sandwich-type electrochemical aptasensor for thrombin detection based on platinum nanoparticles decorated carbon nanocages as signal labels

In this work, a novel and sensitive sandwich-type electrochemical aptasensor has been developed for thrombin detection based on platinum nanoparticles (Pt NPs) decorated carbon nanocages (CNCs) as signal tags. The morphological and compositional of the Pt NPs/CNCs were examined using transmission electron microscopy, X-ray diffraction, and Raman spectroscopy. The results showed that the Pt NPs with about 3-5nm in diameter were well dispersed on the surface of CNCs. The thiolated aptamer was firstly immobilized on the gold electrode to capture the thrombin molecules, and then aptamer functionalized Pt NPs/CNCs nanocomposites were used to fabricate a sandwich sensing platform. Then, the high-content Pt NPs on carbon nanocages acting as hydrogen peroxide-mimicking enzyme catalyzed the reduction of H2O2, resulting in significant electrochemical signal amplification. Differential pulse voltammetry is employed to detect thrombin with different concentrations. Under optimized conditions, the approach provided a good linear response range from 0.05 pM to 20nM with a low detection limit of 10fM. This Pt NPs/CNCs-based aptasensor shows good precision, acceptable stability and reproducibility, which provided a promising strategy for electrochemical aptamer-based detection of other biomolecules.